Where does Epicentrx, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Epicentrx, Inc. ranks #10,316 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Epicentrx, Inc. hold?

Epicentrx, Inc. holds 30 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Epicentrx, Inc.'s Innovation Score?

Epicentrx, Inc. has an Innovation Score of 54.1 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Epicentrx, Inc. focus on?

Epicentrx, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 26 patents, ranking #871 of 7,163 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Epicentrx, Inc.'s patent grant rate increasing or decreasing?

Epicentrx, Inc.'s recent grant velocity is +113% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Epicentrx, Inc.'s patents?

Epicentrx, Inc.'s patents average 21.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Epicentrx, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Epicentrx, Inc.

USPTO PatentsView assignee record - 30 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Epicentrx ranks #10,316 of 49,997 tracked US assignees by granted-patent volume, with 30 patents across 12 technology areas.

#10,316
of 49,997 US assignees by volume: Top 8%
by Innovation Score (54.1/100): 21.1
avg claims per patent: +113%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10316 · US Corporation #10,316 · 30 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 30 grants
UPPER-Q #10,316/49,997
PHOTO-FINISH Echogen Power Systems
CPC-FOCUS A61K · 12 areas
INNOV-PAR 54.1/100
CLAIMS-DENSE 21.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +113% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Echogen Power Systems, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Epicentrx’s 54.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.9 pts (22%) Velocity 17.3 pts (32%) Breadth 12.2 pts (23%) Claim depth 12.6 pts (23%)

Qualcomm Incorporated · highest

85
Bragi · near

54
DeRoyal Industries · near

54
Epicentrx · this assignee

54
MagnaChip Semiconduc… · near

54
MedImmune · near

54
3D Lighting… · lowest

7

What this shows Epicentrx's Innovation Score is 54.1/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Epicentrx?

Each dot is one of Epicentrx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Epicentrx’s own 21.1 claims/patent is ABOVE the 13.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Epicentrx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Epicentrx's grants concentrate

Epicentrx, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 86.7% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2024 (6 grants) versus a trough of 1 in 2019. By volume, Epicentrx sits between Echogen Power Systems, LLC and Eveready Battery Company, Inc..

Epicentrx's three-year grant acceleration

Epicentrx, Inc. shows 13 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Echogen Power Sys…

30
Ecovative Design

30
Edda Technology

30
Eoflow

30
Everseen

30
Edge-works Manufa…

30
Encite

30
Eveready Battery

30
Epicentrx ◀

30

What this shows Epicentrx holds 30 patents at rank #10,314, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Epicentrx

By rank, the assignees closest to #10,314 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Epicentrx's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Epicentrx, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Epicentrx ranks #871 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (54 here).

DeRoyal Industries, Inc. 54 Bragi GmbH 54 MagnaChip Semiconductor, Ltd. 54 MedImmune Limited 54

Epicentrx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Epicentrx, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	6.7%
2016	3	10.0%
2018	2	6.7%
2019	1	3.3%
2020	1	3.3%
2021	3	10.0%
2022	2	6.7%
2023	5	16.7%
2024	6	20.0%
2025partial year	5	16.7%

Which technologies does Epicentrx, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 20

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 12

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 9

C07D - Heterocyclic Compounds 7

C07K - Peptides 5

Y02A - Technologies FOR Adaptation TO Climate Change 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C12Y - Enzymes 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

A61B - DIAGNOSIS; SURGERY; Identification 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Epicentrx, Inc.'s patent record in context - here's where to go next.

Epicentrx, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 86.7% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #10,316 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Epicentrx, Inc. against Echogen Power Systems, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 54.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.